Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Cyclophosphamide,CYC2023-001,2023,USA,MDV,350,62,45,55,27.5,32,85,12,20,35,30,15,60,25,10,5,25,35,25,18,7,3,9,4,30,65,40,FAC,CMF,AC,TC,20,15,10,35,70,55,15,45,40,60,2
Cyclophosphamide,CYC2022-002,2022,Canada,Claim Database,420,68,52,48,28.1,28,78,15,18,32,33,17,55,28,12,5,22,33,27,21,9,4,11,5,35,60,45,CMF,Taxol,AC,Docetaxel,22,13,12,40,75,60,18,42,40,55,3
Cyclophosphamide,CYC2024-003,2024,UK,MDV,280,70,48,52,29.0,35,75,10,22,30,32,16,58,26,11,5,24,31,26,20,8,5,10,6,28,62,38,EC,FEC,CEF,Taxotere,18,17,15,38,72,58,20,40,40,50,2.5
